Can medication for ADHD reduce drug cravings?
ADHD medication does not just help with focus; it can also reduce drug cravings and relapse risk in people who live with both ADHD and addiction. According to the NHS England ADHD Taskforce (2025) and NICE guidance (NG87), stimulant treatment helps balance the brain’s dopamine and norepinephrine systems, improving self-control and emotional regulation, two key factors that make addiction recovery more sustainable.
How ADHD medication affects cravings
Stimulant medicines such as methylphenidate and lisdexamfetamine increase dopamine and norepinephrine activity in the brain’s reward centres. These chemicals play a key role in motivation and craving. When ADHD remains untreated, low dopamine activity can drive self-medication with substances such as alcohol, nicotine, or stimulants. Treating ADHD helps normalise these pathways, reducing the urge to seek that same “reward” through drugs.
The NHS ADHD Taskforce highlights that people with ADHD who receive appropriate medication show improved self-control, less impulsivity, and greater stability, all of which protect against relapse.
What the evidence shows
A major 2025 BMJ cohort study found that people taking ADHD medication were 25% less likely to misuse substances and had significantly fewer suicidal behaviours, transport accidents, and criminal incidents compared with untreated periods.
Meta-analyses and clinical trials published in PubMed confirm that stimulants produce stronger craving reduction and relapse prevention than non-stimulants such as atomoxetine. However, non-stimulants remain important for individuals at higher risk of medication misuse.
The Royal College of Psychiatrists (CR235) supports combining medication with psychological therapies, such as CBT, to achieve the best outcomes for people with ADHD and addiction.
Safe prescribing and shared care
NICE and NHS policy stress that ADHD medication should be prescribed within shared-care arrangements, involving GPs, pharmacists, and specialists. This ensures consistent monitoring, safe dosing, and early identification of any side effects or misuse of concerns.
Shared-care frameworks, now being implemented across NHS trusts, follow NICE guidance and Taskforce recommendations for stepped, holistic management. Private services such as ADHD Certify also operate under these same NICE-aligned standards, offering monitored medication reviews alongside post-diagnostic care.
Takeaway
Evidence from NICE, NHS, and BMJ shows that ADHD medication, especially stimulants, can reduce drug cravings and relapse risk when prescribed safely and reviewed regularly. The key is joined-up, well-monitored care, combining medication, therapy, and lifestyle support to help people achieve lasting recovery and stability.

